Eledon Pharmaceuticals Inc
ELDN2.060USD
-2.040-49.76%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
123.36MMarket Cap
2.00P/E TTM
More Details of Eledon Pharmaceuticals Inc Company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Eledon Pharmaceuticals Inc Info
Ticker SymbolELDN
Company nameEledon Pharmaceuticals Inc
IPO dateSep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
Number of employees31
Security typeOrdinary Share
Fiscal year-endSep 17
Address19800 Macarthur Blvd.
CityIRVINE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92612
Phone19492388090
Websitehttps://eledon.com/
Ticker SymbolELDN
IPO dateSep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
Company Executives of Eledon Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
BlackRock Institutional Trust Company, N.A.
4.88%
First Light Asset Management, LLC
4.34%
Other
68.77%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
BlackRock Institutional Trust Company, N.A.
4.88%
First Light Asset Management, LLC
4.34%
Other
68.77%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.33%
Investment Advisor
20.85%
Investment Advisor/Hedge Fund
13.81%
Venture Capital
5.96%
Corporation
1.36%
Research Firm
0.54%
Pension Fund
0.12%
Bank and Trust
0.12%
Family Office
0.05%
Other
30.87%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
156
40.56M
67.74%
-3.03M
2025Q2
131
39.86M
66.56%
-1.42M
2025Q1
124
39.32M
65.66%
-3.87M
2024Q4
105
38.47M
64.39%
+11.26M
2024Q3
70
19.89M
51.00%
-1.66M
2024Q2
71
20.04M
55.99%
+4.61M
2024Q1
65
11.37M
47.26%
-1.53M
2023Q4
63
10.93M
50.76%
-2.06M
2023Q3
65
10.70M
50.83%
-4.12M
2023Q2
66
11.20M
53.85%
+179.31K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
6.29M
10.51%
--
--
Jun 30, 2025
RA Capital Management, LP
3.57M
5.96%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.32M
5.54%
+365.26K
+12.37%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.92M
4.88%
+2.34M
+406.69%
Jun 30, 2025
First Light Asset Management, LLC
2.60M
4.34%
+271.73K
+11.67%
Jun 30, 2025
Sphera Funds Management Ltd.
1.96M
3.27%
-347.51K
-15.06%
Jun 30, 2025
Woodline Partners LP
1.67M
2.79%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.38M
2.31%
+717.22K
+107.58%
Jun 30, 2025
Blue Owl Capital Holdings LP
1.33M
2.22%
-490.00K
-26.92%
Jun 30, 2025
Ensign Peak Advisors, Inc.
1.26M
2.11%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ALPS Medical Breakthroughs ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Date
Type
Ratio
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
